In the present study, we demonstrated that oral administration of GMP in a prophylactic or therapeutic manner induces a significant reduction in the development of AD by strongly reducing skin inflammation, eosinophils, and mast cells number in dermis and total IgE levels. The gene discussed is IGHE; the disease is Alzheimer disease.